Document Detail

Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.
MedLine Citation:
PMID:  20596749     Owner:  NLM     Status:  In-Data-Review    
Lidamycin (LDM, also known as C-1027) as an anti-cancer agent inhibits growth in a variety of cancer cells by inducing apoptosis and cell cycle arrest. In this study we demonstrated that inhibition of mouse embryonic carcinoma (EC) cell growth using LDM at low concentrations can be attributed to a loss of the cell's self-renewal capability but not to apoptosis or cell death, which can be correlated to the down-regulation of embryonic stem (ES) cell-like genes Oct4, Sox2 and c-Myc. MTT assays showed that LDM inhibited the growth of mouse P19 EC cells in a time- and dose-dependent manner. The EC cells exposed to a low dose (0.01 nM) of LDM lost their capability to generate colonies, as evidenced by the colony forming assay. Flow cytometer analyses demonstrated that LDM induced G1 arrest in exposed EC cells without apoptosis. Real-time qPCR, Western blotting and immunocytochemistry revealed that Oct4, Sox2 and c-Myc were down-regulated in LDM-exposed EC cells, but not adriamycin (ADM)-exposed cells. Furthermore, a combination of the low dose of LDM and ADM significantly reduced the proliferation of the cancer cells than single-agent treatment. This suggested that synergy of ADM and LDM improved chemotherapy. Taking together, our results indicate that LDM can reduce the capability for self-renewal that mouse EC cells possess through the repression of ES cell-like genes, thereby inhibiting carcinoma cell growth. This data also suggests that LDM might have potential for application in CSC-based therapy and be a useful tool for studying ES cell pluripotency and differentiation.
Hong-Ying Zhen; Qi-Hua He; Yong-Zhan Zhen; Shu-Ling Wang; Yi-Nan Liu; Wei-Hua Wu; Xiao-Yan Zhang; Ai-Li Lu; Li Shen
Related Documents :
2317949 - Hl-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis.
21302279 - Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer.
11245599 - Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimula...
19834689 - Bisabololoxide a, one of the main constituents in german chamomile extract, induces apo...
14990389 - Model of the developing tumorigenic phenotype in mammalian cells and the roles of susta...
9466819 - Derivatives of gallic acid induce apoptosis in tumoral cell lines and inhibit lymphocyt...
8567749 - Effect of cell cycle on the regulation of the cell surface and secreted forms of type i...
8921319 - Cell proliferation rates in common cancer target tissues of b6c3f1 mice and f344 rats: ...
23107969 - Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial...
Publication Detail:
Type:  Journal Article     Date:  2010-07-02
Journal Detail:
Title:  Investigational new drugs     Volume:  29     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-09-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1188-97     Citation Subset:  IM    
Department of Cell Biology, Peking University Health Sciences Center, Xue Yuan Road 38, Beijing, 100191, People's Republic of China,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
Next Document:  Hypoxia-inducible factor 1? expression is a prognostic biomarker in patients with astrocytic tumors ...